| Market Cap | 15.86M | P/E | - | EPS this Y | 63.90% | Ern Qtrly Grth | - |
| Income | -19.39M | Forward P/E | -0.73 | EPS next Y | 11.90% | 50D Avg Chg | - |
| Sales | 1.2M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -53.00% |
| Dividend | N/A | Price/Book | 0.96 | EPS next 5Y | - | 52W High Chg | -94.00% |
| Recommedations | 2.00 | Quick Ratio | 1.32 | Shares Outstanding | 3.47M | 52W Low Chg | 37.00% |
| Insider Own | 3.31% | ROA | -105.91% | Shares Float | 2.76M | Beta | 1.36 |
| Inst Own | 22.49% | ROE | -213.51% | Shares Shorted/Prior | 149.04K/144.33K | Price | 0.44 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 178,832 | Target Price | 30.00 |
| Oper. Margin | -609.42% | Earnings Date | Nov 12 | Volume | 109,268 | Change | 4.05% |
TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It also develops other dry powder products, such as Augmenta human derived monoclonal antibodies for the treatment of COVID-19 disease; and other vaccines. It has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs. TFF Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Fort Worth, Texas.
| Roth MKM | Buy | Mar 28, 24 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| CARLSON CAPITAL L P | 10% Owner 10% Owner | Aug 15 | Sell | 0.41 | 216,000 | 88,560 | 5,064,000 | 08/17/23 |
| Weisman Harlan F | President and CEO President and CEO | Aug 15 | Buy | 0.25 | 600,000 | 150,000 | 814,615 | 08/15/23 |
| ROCAMBOLI STEPHEN | Director Director | Aug 15 | Buy | 0.25 | 20,000 | 5,000 | 36,000 | 08/15/23 |
| Roberts Brandi | Director Director | Aug 15 | Buy | 0.25 | 20,000 | 5,000 | 20,000 | 08/15/23 |
| COLEMAN KIRK ALLEN | Chief Financial Offi.. Chief Financial Officer | Aug 15 | Buy | 0.25 | 20,000 | 5,000 | 35,675 | 08/15/23 |
| MILLS ROBERT S | Director Director | Aug 15 | Buy | 0.25 | 40,000 | 10,000 | 55,980 | 08/15/23 |
| Mikhak Zamaneh | Chief Medical Office.. Chief Medical Officer | Aug 15 | Buy | 0.25 | 120,000 | 30,000 | 135,000 | 08/15/23 |
| COLEMAN KIRK ALLEN | Chief Financial Offi.. Chief Financial Officer | Mar 10 | Buy | 0.7881 | 12,000 | 9,457 | 15,675 | 03/13/23 |
| Weisman Harlan F | President and CEO President and CEO | Mar 10 | Buy | 0.8789 | 150,000 | 131,835 | 214,615 | 03/13/23 |
| Mikhak Zamaneh | Chief Medical Office.. Chief Medical Officer | Mar 10 | Buy | 0.82 | 15,000 | 12,300 | 15,000 | 03/13/23 |
| Weisman Harlan F | President and CEO President and CEO | Dec 15 | Buy | 1.06 | 50,000 | 53,000 | 64,615 | 12/19/22 |
| Fletcher Aaron G.L. | Director Director | Nov 22 | Buy | 1.15 | 43,470 | 49,990 | 143,470 | 11/23/22 |
| Weisman Harlan F | Director Director | May 18 | Buy | 5.31 | 7,115 | 37,781 | 14,615 | 05/20/22 |
| Fletcher Aaron G.L. | Director Director | May 16 | Buy | 4.97 | 109,600 | 544,712 | 109,600 | 05/17/22 |
| Weisman Harlan F | Director Director | May 16 | Buy | 4.74 | 2,500 | 11,850 | 7,500 | 05/17/22 |
| COLEMAN KIRK ALLEN | Chief Financial Offi.. Chief Financial Officer | May 16 | Buy | 4.62 | 1,675 | 7,738 | 3,675 | 05/17/22 |
| Mattes Glenn R. | President and CEO President and CEO | May 16 | Buy | 4.78 | 16,000 | 76,480 | 36,000 | 05/17/22 |
| ROCAMBOLI STEPHEN | Director Director | May 16 | Buy | 4.54 | 3,000 | 13,620 | 18,722 | 05/17/22 |
| Fletcher Aaron G.L. | Director Director | Apr 04 | Buy | 6.66 | 542,000 | 3,609,720 | 542,000 | 04/04/22 |